Hoth Therapeutics Inc., a biopharmaceutical company specializing in treatments for rare and inflammatory diseases, has announced positive preclinical safety data for its investigational oncology candidate, HT-KIT. The study results, which have already been presented, demonstrated a dose-dependent increase in liver mass without any observed toxicity or adverse effects on other organs such as the kidney, spleen, and thymus. The findings support the safety profile of HT-KIT, with no visible lesions or gross pathology noted in treated animals. Hoth Therapeutics plans to proceed with GLP toxicology studies and aims to submit an Investigational New Drug $(IND.AU)$ application, marking a key step toward future clinical trials.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。